Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-08-12 16:56:01 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2213-2600(23)00158-3
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213260023001583
其他信息:
出版社: Elsevier BV
作者: Bruno François; Simon Lambden; Tom Fivez; Sebastien Gibot; Marc Derive; Jean-Marie Grouin; Margarita Salcedo-Magguilli; Jérémie Lemarié; Nicolas De Schryver; Ville Jalkanen; Tarik Hicheur; Jean-Jacques Garaud; Valérie Cuvier; Ricard Ferrer; Morten Bestle; Ville Pettilä; Jean-Paul Mira; Camille Bouisse; Emmanuelle Mercier; Joris Vermassen; Vincent Huberlant; Isabelle Vinatier; Nadia Anguel; Mitchell Levy; Pierre-François Laterre; Pierre Asfar; Mai-Anh Nay; Christophe Guitton; Jean-Pierre Quenot; David Tran-Van; Julien Bohe; Gaëtan Plantefève; Saadalla Nseir; Jean-Yves Lefrant; Xavier Monnet; Laurent Papazian; Christophe Vinsonneau; Jean-Michel Constantin; Alexandre Mebazaa; Haikel Oueslati; Dolores Escudero; Fernando Martinez Sagasti; Enrique Piacentini; Paula Ramirez Galleymore; Thierry Dugernier; David Fagnoul; Isabelle Michaux; Allan Seibert; Matti Reinikainen; Thorbjørn Grøfte; Ignacio Martin-Loeches; John Laffey
